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AS Whittemore6, S Kru¨ger-Kjaer3,9, CL Pearce6, PDP Pharoah2 and SA Gayther*,1
1Gynaecological Oncology Department, UCL EGA Institute for Women’s Health, University College London, London, UK; 2Strangeways Research
Laboratory, CR-UK Department of Oncology, University of Cambridge, Cambridge, UK; 3Department of Virus, Hormones and Cancer, Institute of Cancer
Epidemiology, Danish Cancer Society, Copenhagen, Denmark; 4Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA;
5Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA; 6Department of Preventive Medicine, University of
Southern California, Keck School of Medicine, Los Angeles, CA, USA; 7JD Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson
Cancer Research Center, Seattle, WA, USA; 8Department of Epidemiology and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; 9Gynaecology
Clinic, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Denmark, CR-UK; 10Department of Gynaecology and Obstetrics, Aarhus
University Hospital, Skejby, Aarhus, Denmark; 11Department of Oncology, Strangeways Research Laboratory, Genetic Epidemiology Unit, University of
Cambridge, Cambridge, UK
Low–moderate risk alleles that are relatively common in the population may explain a significant proportion of the excess familial risk
of ovarian cancer (OC) not attributed to highly penetrant genes. In this study, we evaluated the risks of OC associated with common
germline variants in five oncogenes (BRAF, ERBB2, KRAS, NMI and PIK3CA) known to be involved in OC development. Thirty-four
tagging SNPs in these genes were genotyped in B1800 invasive OC cases and 3000 controls from population-based studies in
Denmark, the United Kingdom and the United States. We found no evidence of disease association for SNPs in BRAF, KRAS, ERBB2
and PIK3CA when OC was considered as a single disease phenotype; but after stratification by histological subtype, we found
borderline evidence of association for SNPs in KRAS and BRAF with mucinous OC and in ERBB2 and PIK3CA with endometrioid OC.
For NMI, we identified a SNP (rs11683487) that was associated with a decreased risk of OC (unadjusted Pdominant¼ 0.004).
We then genotyped rs11683487 in another 1097 cases and 1792 controls from an additional three case–control studies from the
United States. The combined odds ratio was 0.89 (95% confidence interval (CI): 0.80–0.99) and remained statistically significant
(Pdominant¼ 0.032). We also identified two haplotypes in ERBB2 associated with an increased OC risk (Pglobal¼ 0.034) and a
haplotype in BRAF that had a protective effect (Pglobal¼ 0.005). In conclusion, these data provide borderline evidence of association
for common allelic variation in the NMI with risk of epithelial OC.
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Globally, ovarian cancer (OC) is responsible for approximately
125 000 deaths each year (Parkin et al, 2005). The risk to first-
degree relatives of an OC case is increased above population rates
(Stratton et al, 1997) and twin studies suggest that genes are more
important than shared environment (Lichtenstein et al, 2000);
however, most cases occur without any obvious evidence of
inherited susceptibility (i.e., they appear to be sporadic). The two
highly penetrant susceptibility genes BRCA1 and BRCA2 are
responsible for approximately half of all families containing two or
more ovarian cancer cases (Ford et al, 1998; Gayther et al, 1999;
Ramus et al, 2007), but these genes account for less than 40% of
the familial excess risk of OC (Antoniou and Easton, 2006). The
remaining familial risks are thought to be due to combinations of
multiple alleles that confer moderate- or low-penetrance suscept-
ibility (Pharoah et al, 2002).
The most widely used approach to identify moderate/low-risk
susceptibility alleles for cancer has been to study candidate genes
in biologically relevant pathways. Proto-oncogenes are essential
for normal cell function, particularly in the regulation of cell
division, proliferation, survival, motility and apoptosis. Activating
mutations or amplification of these genes generally elevates growth
factor production and stimulates cell mitosis leading to neoplastic
transformation (Rhim, 1988; Hogdall et al, 2003a). To date, few
studies have reported on the OC risks associated with germline
genetic variation in proto-oncogenes. A variant of borderline
significance has been reported in the putative oncogene AURKA
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(earlier known as STK15) (Dicioccio et al, 2004). However, this was
not confirmed in a larger consortium study (Ramus et al, 2008).
Most of the oncogenes known to be altered in OC development
have not yet been studied.
Of the oncogenes known to be involved in OC, KRAS is the most
frequently mutated (Forbes et al, 2006). KRAS functions in the
receptor tyrosine kinase pathway (Gemignani et al, 2003) and
several other genes that function in this pathway are mutated in
multiple tumour types (Cuatrecasas et al, 1997). Activating
mutations of KRAS appear to be an early event in OC development,
but predominantly tumours of the mucinous histological subtype
(Gemignani et al, 2003). Mutations in codons 12 and 13 have been
detected in approximately 50% of mucinous OCs (Gemignani et al,
2003). BRAF, in the mitogen-activated protein kinase pathway, is a
downstream effector of KRAS and is critical in the transduction of
cell growth signals (Cuatrecasas et al, 1998). Overexpression of
BRAF has been found in a variety of cancers, and mutations have
been reported in 12% of OCs (Gemignani et al, 2003; Russell and
McCluggage, 2004; Sieben et al, 2004).
PIK3CA is the catalytic subunit of the lipid kinase phosphatidyl-
inositol 3-kinase (PIK), which is involved in the regulation of cell
proliferation, adhesion transformation, survival, apoptosis and
motility (Volinia et al, 1994; Fruman et al, 1998; Cantley, 2002).
The helical and kinase domains of PIK3CA are hotspots for
mutations, which have been found in multiple tumour types
including ovary, breast, lung, brain, colon and stomach (Muller
et al, 2007). PIK3CA mutations have been shown to correlate with
increased gene expression in several OC cells lines. Detectable
amplification of the gene has also been shown in 58% of
ovarian tumours using fluorescence in situ hybridisation
(Shayesteh et al, 1999).
The human epidermal growth factor receptor-2 gene, ERBB2
(HER-2/Neu), is a transmembrane protein that acts as a growth
factor receptor and is involved in cell proliferation and cell
differentiation (Wu et al, 2004). Breast, prostate, lung, gastrointest-
inal, kidney, liver and bladder cancers have all shown an elevated
expression of ERBB2 (Wu et al, 2004). For OC, 20–30% of primary
stage III/IV tumours show ERBB2 overexpression (Hellstrom et al,
2001). Protein expression using antibody staining on a subset of
ovarian tumours from the MALOVA study showed that 39% of the
carcinomas overexpressed ERBB2 (Hogdall et al, 2003b).
The MYC family of proto-oncogenes, including NMYC and
MYC, and their interacting partners, are transcription factors that
have a well-documented role in tumourigenesis. MYC over-
expression caused by gene amplification induces uncontrolled
hyper-proliferation and occurs in B35% of epithelial OCs.
Another gene, the NMYC and STAT interactor (NMI), which
interacts with NMYC, MYC, MAX, FOS, other transcription factors
(Zhu et al, 1999) and BRCA1 (Li et al, 2002), is overexpressed in
human leukaemias and other cancers (Bao and Zervos, 1996).
The aim of this study was to evaluate the risks of OC associated
with common genetic variation in five of the candidate oncogenes
described above – BRAF, ERBB, KRAS, NMI and PIK3CA – using a
SNP-tagging approach. To do this, we genotyped 34 common tagging
SNPs (tSNPs) in 1816 invasive epithelial OC cases and 3000
unaffected controls from five different case–control studies from
the United States, United Kingdom and Denmark as part of a multi-
centre collaboration. We then evaluated one positive finding in a
further 1097 cases and 1712 controls from three other US studies.
MATERIALS AND METHODS
Study individuals
In the first stage of this study, we genotyped OC cases and controls
from five different populations. These were (1) The Danish
MALOVA study (446 cases and 1221 controls); (2) The UK
SEARCH study (730 cases and 855 controls); (3) The Genetic
Epidemiology of Ovarian Cancer Study (GEOCS; previously FROC)
from Stanford, CA, USA (327 cases and 429 controls); (4) The USC
(A) study from Los Angeles, CA, USA (197 cases and 224 controls);
and (5) the UKOPS study from the United Kingdom (116 cases and
271 controls). In stage 2, a putative positive association was
followed up in three other case–control studies: (1) The USC (B)
study, CA, USA (237 cases and 360 controls); (2) The DOVE study,
Seattle, WA, USA (584 cases and 716 controls); and (3) The HOPE
study, Pittsburgh, USA (276 cases and 636 controls). USC (A) and
(B) are subsets of the same USC population. The USC (A) samples
were collected between 2000 and 2004 and USC (B) samples were
collected from 1993 to 1999. All study individuals were non-
Hispanic Whites. Details for several of these studies have been
published before (Dicioccio et al, 2004; Pearce et al, 2005; Song
et al, 2006, 2007; Gayther et al, 2007; Rossing et al, 2007) and are
summarised in Table 1. Local ethics committee approval was given
for the collections and genotyping in all individuals.
Candidate gene and tSNP selection
We chose to analyse candidate oncogenes for which there is
evidence that the genes were amplified or mutated in OCs. The
genes we chose to examine initially were BCL2, BRAF, MYC,
CTNNB1, EGFR, ERBB2, FGF3, HRAS, KIT, MDM2, NMI and
PIK3CA. Some of these genes were excluded if no HapMap
genotyping data were available, if the gene was poorly tagged or if
there were o3 tSNPs or 415 tSNPs in the genes. We used data
from the CEPH population, from The International HapMap
Project Data Rel 20/phase II Jan06 (www.hapmap.org), Haploview
version 3.32 (Barrett et al, 2005) and Tagger (de Bakker et al, 2005)
to select tSNPs that capture common genetic variation in each
candidate gene, and putative regulatory regions up and down-
stream of the gene (within 5 kb), with a minimum squared
correlation of 0.8 (r2X0.8). The multi-marker (aggressive) tagging
option of Tagger was used to select tSNPs. If a selected tSNP failed
assay design or genotyping, an alternative tagging SNP was chosen.
Genotyping SNPs
A combination of iPLEX (Sequenom Inc., Hamburg, Germany)
and TaqMan ABI 7900HT Sequence Detection System (Applied
Biosystems, Warrington, UK) was used to genotype the samples as
described earlier (Zhao et al, 2006). The MALOVA and SEARCH
samples were genotyped by a combination of TaqMan and iPLEX;
UKOPS, USC and GEOCS were genotyped with TaqMan only.
Genotyping with iPLEX was performed at the Sequenom
laboratory in Hamburg, Germany. TaqMan genotyping of stage 1
samples was performed at the Gynaecological Cancer Research
Laboratories, University College London, and Strangeways
Research Laboratory, University of Cambridge (both UK). For
stage 2, samples were genotyped by TaqMan at the Keck School of
Medicine, University of Southern California, USA. Genotyping was
repeated for studies/plates when call rates were below 90%, if there
were discordant duplicate samples or if negative controls tested
positive (Song et al, 2006, 2007; Gayther et al, 2007).
Statistical methods
Deviation from Hardy–Weinberg equilibrium (HWE) was
assessed in controls within study populations using the standard
w2 test. Unconditional logistic regression was used to assess the
relationship between each tSNP and risk of OC for each study and
pooled across studies (stratified by study), with the primary test of
association being a test for trend (Ptrend). The per-allele odds ratio
and odds ratios for the heterozygote and rare homozygote relative
to the common homozygote were estimated by stratified logistic
regression. The programme TagSNPs (Stram et al, 2003) was used
tSNPs in oncogenes and ovarian cancer susceptibility
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to model the relevant multi-marker haplotypes resulting from
aggressive SNP tagging. Heterogeneity between study strata was
tested by comparing logistic regression models with and without a
genotype–stratum interaction term using the likelihood ratio test.
All the reported P-values are two sided. There was no association
in controls between age and genotype frequency for any of the
SNPs, and adjusting for age did not materially alter the effect
estimates and thus age was not included in the models (data not
shown). Where there was evidence for association, we compared
the fit of log-additive co-dominant, dominant and recessive genetic
models using likelihood ratio tests.
We also conducted analyses to determine if haplotype effects
were present. Haplotype blocks (regions of strong linkage
disequilibrium) were defined using the confidence interval option
of Haploview (Gabriel et al, 2002), with minor adjustments to
include adjacent SNPs, but maintaining the cumulative frequency
of the common haplotypes to 490%. All genes had one haplotype
block, except KRAS, which had two blocks. Haplotype analysis was
conducted using the programme TagSNPs (Stram et al, 2003).
TagSNPs implements an expectation –substitution approach to
account for the uncertainty caused by the unphased genotype data
(Stram et al, 2003). The genotype data for GEOCS, MALOVA,
SEARCH, UKOPS and USC (A) samples were used in this analysis.
Unconditional logistic regression was used to test the association
between each haplotype relative to the most common haplotype
(Zaykin et al, 2002; Stram et al, 2003). Haplotypes that occurred
with a frequency of 2% or greater in the combined data were
considered ‘common’, and those with less than 2% frequency were
pooled together as rare haplotypes.
RESULTS
Forty SNPs were selected to tag the common genetic variation in
BRAF, ERBB2, KRAS, NMI and PIK3CA. Six of these (PIK3CA:
rs1607237, rs6443624 and rs3729692; KRAS: rs11047912 and
rs17388893; BRAF: rs11771946) failed assay design, manufacture
or genotype testing and could not be efficiently tagged by any
Table 1 Ovarian cancer case–control populations included in this study
Controls Cases
Population* Total Age
Participation
rate (%) Ascertainment Total Age
Participation
rate (%) Ascertainment
MALOVA
(Denmark)
1221 35–79 67 Random selection of females from
the computerised Central
Population Register.
446 35–79 79 Incident cases diagnosed between
1994 and 1999 from municipalities
of Copenhagen and Frederiksberg
and surrounding counties.
SEARCH (UK) 855 39–77 84 Selected from the EPIC-Norfolk
cohort of 25 000 individuals based
in the same geographical regions as
the cases.
730 21–74 69 Cases from East Anglian West
Midlands and Trent regions of
England. Prevalent cases diagnosed
between 1991 and 1998; incident
cases diagnosed 1998 onwards.
GEOCS (USA) 429 19–66 75 Random-digit dial identification
from study area. Frequency
matched to cases for race/ethnicity
and 5-year age group.
327 23–64 75 Consecutive cases diagnosed from
1997 to 2002 in Greater Bay Area
Cancer Registry San Francisco.
USC (A) (USA) 224 21–78 73 Neighbourhood recruited controls,
frequency matched to cases for age
and ethnicity from 2000 to 2004.
197 18–84 73 Rapid case ascertainment through
Los Angeles Cancer Surveillance
programme from 2000 to 2004.
UKOPS (UK) 271 50–76 97 Apparently healthy
postmenopausal women from the
general population participating in
the United Kingdom Collaborative
Trial of Ovarian Cancer Screening
(UKCTOCS). All women followed
up for cancers through the Office
of National Statistics.
116 35–86 86 Incident cases from 10
gynaecological oncology National
Health Service centres throughout
the United Kingdom, from January
2006 onwards.
Total (stage 1) 3000 1816
USC (B) (USA) 360 21–78 73 Controls recruited from same
neighbourhoods as cases from
1993 to 1999, frequency matched
to cases for age and ethnicity.
237 18–84 73 Cases recruited through the Los
Angeles Cancer Surveillance
programme from 1993 to 1999.
DOVE (USA) 716 35–74 82 Random-digit dial identification
from study area. Frequency
matched to cases for race/ethnicity
and 5-year age group.
584 35–74 75 Cases diagnosed with primary
invasive ovarian cancer between
2002 and 2005 from a 13-county
area of Western Washington state.
HOPE (USA) 636 25–80 81 Identified in same regions as cases.
Frequency matched for age and
ethnicity. All participants undergo
home interviews.
276 25–80 69 Variable source including physician
offices cancer registries and
pathology databases from counties
of Western PA Eastern OH and
Western NY.
Total (stage 2) 1792 1097
TOTAL (stages
1 and 2)
4712 2913
*All samples are population based. All individuals are non-hispanic Whites.
tSNPs in oncogenes and ovarian cancer susceptibility
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other SNP. Therefore, we were able to genotype 34 SNPs in total
(Table 2). The tSNPs were selected using HapMap Data Rel 20/
phase II on NCBI B35 assembly, dbSNP b125. For all five genes, we
captured 176 of 188 (94%) common SNPs with r240.8. Tagging
efficiencies were the same using the most recent HapMap data
release (HapMap Data Rel 21a/phase II on NCBI B35 assembly
dbSNPb125), which captured 199 of 212 (94%) of the common
SNPs with r240.8.
This panel of SNPs was genotyped in five different OC
case–control studies from the United Kingdom (SEARCH and
UKOPS), United States (GEOCS and USC (A)) and Denmark
(MALOVA). Combined, these studies comprise 1816 invasive
epithelial OC cases and 3000 unaffected female controls. For most
tSNPs, genotype distributions in controls were consistent with
HWE in all populations in which genotyping passed quality control
criteria. For one SNP (rs2699905), controls from GEOCS, SEARCH
and UKOPS deviated significantly from HWE (Po0.01). Seven
tSNPs (rs2952155, rs11047917, rs11551174, rs10487888, rs2865084,
rs1733832 and rs289831) could not be genotyped for GEOCS,
UKOPS and USC (A) because Taqman assays for these tSNPs failed
assay manufacture. This is reflected in the variable numbers of
cases and/or controls that were successfully genotyped for each
tSNP, listed in Table 3.
Association between genotype frequencies and OC risk
We found no evidence of association between tSNPs or multi-
marker haplotypes in BRAF, ERBB2, KRAS and PIK3CA and
susceptibility to invasive epithelial OC (Table 3 and Supplementary
Table 1). A SNP in NMI (rs11683487) showed evidence of
association with reduced risk of OC (heterozygous odds ratio
(OR) 0.80 (95% confidence interval (CI) 0.69–0.93); homozygous
OR 0.87 (95% CI 0.71– 1.02); Ptrend¼ 0.038) (Table 3). The best-
fitting genetic model for this SNP was a dominant model
(P¼ 0.004) (rare allele carriers vs common allele homozygotes
OR 0.81 (95% CI 0.71–0.94)). There was no statistically significant
heterogeneity across studies for any SNP.
The association with rs11683487 was investigated further by
performing a second stage of genotyping in three additional
populations from the United States (USC (B); DOVE and HOPE)
(Table 1). Together, these three studies comprised an additional
1097 cases and 1712 controls. There was no association between
rs11683487 and the risk of OC in the samples used for validation
on their own (Pdominant¼ 0.92; OR¼ 1.01 (0.85–1.20)). After
combining the data from both stages, the association with
rs11683487 was weaker, but still statistically significant
(Pdominant¼ 0.032; OR¼ 0.89 (0.80–0.99); Figure 1A; Supplementary
Table 2).
Earlier studies have shown that different histological subtypes of
OC have different genetic and biological backgrounds and are
associated with different aetiological pathways. Therefore, we
stratified cases by histological subtype and repeated the analyses.
In the combined sample set, there were 859 OC cases of the serous
histological subtype, 274 endometrioid cases, 192 mucinous cases
and 138 clear-cell cases. We found no additional evidence of genetic
associations in the serous subtype, but we did find borderline
evidence of association for one SNP each in the ERBB2 and PIK3CA
genes with endometrioid OC and for three SNPS each in the BRAF
and KRAS genes and one SNP in the NMI gene, all associated with
mucinous OC. These data are summarised in Table 4.
We performed tests of association with common haplotypes for
the five genes. There was no evidence of association with OC risk
for haplotypes in KRAS and PIK3CA (Table 5). We found
statistically significant haplotype effects for BRAF, ERBB2 and
NMI. Two haplotypes from ERBB2 were associated with an
increased OC risk, h233 (OR¼ 1.17 (1.02 –1.34), P¼ 0.022) and
h411 (OR¼ 1.19 (1.03–1.37), P¼ 0.016), respectively. A haplotype
in BRAF, h333423241, was associated with a decrease in the risk of
OC (OR¼ 0.81 (0.68– 0.95), P¼ 0.012). Global tests of association
were significant for BRAF (P¼ 0.005) and ERBB2 (P¼ 0.034). The
association observed with the NMI haplotype was fully explained
by the single tSNP association.
DISCUSSION
Somatic alterations that activate proto-oncogenes and drive cells
towards unregulated proliferation are a well-documented feature
of all cancers. It has also become clear that different combinations
of oncogenes contribute to the development of different tumour
types. BRAF, ERBB2, KRAS and PIK3CA are all oncogenes shown
to be involved in OC development, and NMI interacts with the
oncogenes NMYC, MYC, MAX and FOS. NMI has also been shown
to form a complex with MYC and BRCA1 and therefore may play a
role in breast cancer and OC (Li et al, 2002). In this study, we
evaluated the association between 34 tSNPs in these genes and the
risk of invasive epithelial OC using a case–control study design.
To our knowledge, none of these genes has been investigated
before for their association with invasive OC.
Table 2 tSNPs identified after genotyping in ovarian cancer cases and controls
HapMap data Gene All SNPs
Criteria
SNPs
Tagging
SNPs
SNPs
genotyped
SNPs
captured r240.8
SNPs
captured r240.8 (%)
SNPs
captured r240.5
Release 20a BRAF 158 75 9 8 72/75 96 72/75
ERBB2 16 6 3 3 6/6 100 6/6
KRAS 59 46 11 9 42/46 91 44/46
NMI 45 25 6 6 25/25 100 25/25
PIK3CA 53 36 11 8 33/36 92 34/36
Total 331 188 40 34 176/188 94 181/188
Release 21ab BRAF 164 75 9 8 72/75 96 72/75
ERBB2 26 11 5 3 9/11 82 9/11
KRAS 69 55 11 9 50/55 91 53/55
NMI 52 32 6 6 32/32 100 32/32
PIK3CA 60 39 11 8 36/39 92 39/39
Total 371 212 42 34 199/212 94 205/212
SNP¼ single-nucleotide polymorphism. Criteria SNPs: minor allele frequencyX0.05; Hardy–Weinberg equilibriumX0.01. The captured SNPs refer to the number and
proportion of criteria SNPs covered by the HapMap release. aThe tagging SNPs genotyped were selected using HapMap Data Release 20. bThe genes were retagged using the
new HapMap data release (21a), and the proportion of SNPs that were captured by the SNPs genotyped was determined.
tSNPs in oncogenes and ovarian cancer susceptibility
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We found borderline evidence for a statistically significant
association with disease risk for a tSNP, rs11683487, in intron 1 of
the NMI gene. The common allele (G) occurs in the Caucasian
population with a frequency of approximately 58% and we
observed that the rare allele (T) was associated with a decreased
risk of OC. The association for rs11683487 may be a false positive.
Where the prior probability of association is low, very stringent
significance levels are required to ensure that a detected
association is true positive. Genome-wide significance is generally
considered to be Po107 (Thomas et al, 2005). False-positive
associations due to population stratification is also possible, but
this seems an unlikely explanation for data from multiple studies
from different populations in which the analyses were restricted to
white subjects.
If the association we identified in NMI is real, then this could be
either due to a direct causal effect of the tSNP or because the SNP
is in linkage disequilibrium with the true causal variant, possibly
in a different gene. NMI enhances the transcription of several other
genes altered in OCs (MYC; N-MYC) when it is induced by
interleukin-2 and interferon-g. The role of MYC amplification in
ovarian and other cancers is well established. A detailed mapping
of SNPs at a locus on chromosome 8q, near MYC, has recently
provided substantial evidence that this locus is associated with
susceptibility to breast, prostate and ovarian cancer (Ghoussaini
et al, 2008). A further link comes from the finding that NMI forms
a complex with MYC and BRCA1 (Li et al, 2002).
The NMI SNP rs11683487 tags eight other SNPs with r240.8,
one of which is a non-synonymous coding SNP (rs1048135) tagged
with an r2¼ 1, and the rare (G) allele codes for leucine instead of
serine. We examined whether there is any evidence supporting the
role of these SNPs in abrogating NMI function. The programme
PMut (Ferrer-Costa et al, 2005) predicted that the rare allele
(coding for leucine), with a score of 3/10 had a ‘pathological
significance’ and was classed as ‘damaging’ using the SIFT
programme (Cheng et al, 2006). The bioinformatics tool, PupaSNP
(http://pupasuite.bioinfo.cipf.es/) (Conde et al, 2006; Reumers
et al, 2008), also suggested that this allele may disrupt the binding
of exonic splicing enhancers. In addition, PupaSNP indicated that
rs11683487 and rs11730 may have transcription and translation
regulatory functions, and that rs11730 may affect exon splicing.
We found no evidence of association with disease risk for
polymorphisms in BRAF, ERBB2, KRAS and PIK3CA at Pp0.05,
when OC was considered as a single disease phenotype. The
combined sample size from five studies provides 98% power at the
5% significance level to detect a co-dominant allele with a
frequency of 0.3 that confers a relative risk of 1.2, and 95% power
Table 3 Genotype-specific risks (OR and 95% CI) of pooled stage 1 data
Gene SNP name Case Control MAF HetORa (95% CI) HomORa (95% CI) Ptrend
BRAF rs10487888b 1680 2694 0.47 1.09 (0.93–1.28) 1.02 (0.86–1.22) 0.9
rs1733832b,c,d 1159 2043 0.06 1.08 (0.86–1.36) 3.39 (0.96–11.89) 0.2
rs1267622 1751 2880 0.24 0.99 (0.87–1.12) 0.97 (0.75–1.26) 0.79
rs13241719 1602 2488 0.31 0.98 (0.85–1.12) 0.86 (0.69–1.08) 0.27
rs17695623 1744 2901 0.07 0.97 (0.81–1.16) 1.14 (0.52–2.46) 0.86
rs17161747 1771 2909 0.5 1.13 (0.93–1.38) 1.29 (0.57–2.93) 0.18
rs17623382 1764 2900 0.12 1.01 (0.87–1.17) 1.01 (0.61–1.66) 0.9
rs6944385 1758 2893 0.14 1.14 (0.99–1.32) 0.99 (0.66–1.50) 0.14
rs1267622, rs6944385; AA 1786 2948 0.76 1.02 (0.79–1.33) 1.04 (0.80–1.34) 0.77
ERBB2 rs2952155d 1667 2678 0.24 1.01 (0.89–1.15) 1.11 (0.84–1.47) 0.57
rs2952156 1766 2912 0.29 0.97 (0.86–1.10) 1.15 (0.89–1.49) 0.74
rs1801200 1766 2916 0.22 1.04 (0.92–1.19) 1.01 (0.77–1.31) 0.64
KRAS rs12305513 1788 2934 0.1 0.87 (0.74–1.03) 0.71 (0.38–1.31) 0.053
rs12822857 1751 2901 0.47 1.01 (0.88–1.17) 0.94 (0.80–1.12) 0.53
rs10842508 1776 2935 0.25 0.97 (0.86–1.10) 0.95 (0.73–1.22) 0.57
rs12579073 1765 2900 0.48 0.97 (0.84–1.12) 0.92 (0.78–1.09) 0.36
rs10842513 1770 2878 0.09 1.03 (0.87–1.21) 0.93 (0.50–1.74) 0.86
rs4623993 1748 2892 0.16 0.96 (0.83–1.10) 1.13 (0.77–1.67) 0.85
rs6487464 1763 2895 0.38 1.04 (0.91–1.18) 0.99 (0.82–1.19) 0.94
rs10842514 1757 2886 0.44 0.98 (0.86–1.13) 1.08 (0.91–1.29) 0.42
rs11047917b,c 1476 2456 0.06 0.92 (0.75–1.14) 1.62 (0.57–4.57) 0.71
rs4623993, rs12579073; TC 1717 2818 0.1 0.96 (0.80–1.15) 0.94 (0.56–1.57) 0.63
rs12822857, rs10842508; AC 1730 2857 0.23 0.99 (0.87–1.13) 1.04 (0.80–1.36) 0.93
rs12822857, rs10842514; GT 1715 2806 0.4 1.04 (0.91–1.20) 1.12 (0.94–1.34) 0.23
rs12822857, rs12579073, rs6487464; GAC 1689 2746 0.39 1.04 (0.89–1.21) 1.06 (0.88–1.29) 0.51
NMI rs394884 1708 2852 0.15 1.01 (0.88–1.17) 1.40 (0.84–2.32) 0.47
rs11551174b,c,d 1159 2040 0.06 0.96 (0.76–1.23) 1.23 (0.45–3.38) 0.92
rs289831 1665 2718 0.13 1.05 (0.91–1.22) 1.08 (0.61–1.89) 0.48
rs3771886 1764 2927 0.41 1.03 (0.90–1.18) 1.19 (1.00–1.42) 0.075
rs11683487 1464 2564 0.46 0.80 (0.69–0.93) 0.87 (0.71–1.02) 0.038
rs2113509 1776 2944 0.13 1.05 (0.91–1.21) 1.16 (0.68–1.97) 0.42
PIK3CA rs2865084b,c,d 1164 2046 0.06 1.14 (0.89–1.45) 0.43 (0.37–0.50) 0.29
rs7621329 1749 2818 0.16 0.99 (0.86–1.13) 1.23 (0.86–1.77) 0.64
rs1517586 1739 2908 0.1 0.98 (0.83–1.15) 0.77 (0.42–1.40) 0.54
rs2699905 1741 2855 0.27 1.01 (0.88–1.15) 0.89 (0.71–1.11) 0.49
rs7641889 1779 2939 0.07 0.89 (0.74–1.07) 1.28 (0.58–2.84) 0.38
rs7651265 1794 2883 0.1 0.89 (0.76–1.04) 1.58 (0.89–2.80) 0.54
rs7640662 1765 2916 0.15 1.02 (0.89–1.17) 0.85 (0.57–1.27) 0.86
rs2677760 1762 2925 0.49 1.01 (0.87–1.16) 1.04 (0.88–1.23) 0.67
CI¼ confidence interval; MAF¼minor allele frequency; OR¼ odds ratio; SNP¼ single-nucleotide polymorphism. aCompared with common homozygote. bUKOPS is excluded.
cUSC is excluded. dGEOCS is excluded. Bold text indicates positive results, either by P-value or CI ranges that do not cross 1.00.
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to detect a dominant allele with a frequency of 0.1 that confers a
relative risk of 1.3. It is therefore unlikely that the common tagged
variants in these genes contribute significantly to OC risk.
However, we cannot rule out the possibility that associations exist
for the known poorly tagged variants. With the most recent
HapMap data (release 21a), of the 212 common variants, 199 were
tagged with r240.8 and 205 with r240.5. Furthermore, even
though tSNPs based on HapMap data are likely to tag most of the
common SNPs, there is a possibility that other unknown common
variants were poorly tagged, or that less common variants in these
genes that influence disease susceptibility exist.
We must also consider the possibility that common variants
within these genes confer susceptibility to specific subtypes of OC.
There is evidence in the literature that the genetic changes
associated with OC development differ for different histological
subtypes (reviewed in Elmasry and Gayther, 2005). For example,
somatic activating KRAS mutations are found to some extent in
most OC subtypes, but are much more common in mucinous
ovarian tumours. Also, germline BRCA1 and BRCA2 mutations
tend to predispose to serous OCs (Lakhani et al, 2004). We found
some evidence of association with disease risk for different
histological subtypes, for SNPs in all five of the oncogenes studied,
and it is perhaps interesting that SNPs in the KRAS gene and its
downstream effector BRAF were associated with mucinous OC.
However, the sample sizes after subtype stratification meant that
these studies had insufficient power to detect associations at
stringent levels of statistical significance, and so the data must be
treated with caution. Much larger sample sizes, gathered through
the ovarian cancer association consortium (OCAC), will be needed
to establish if any of these associations are real.
Haplotype analysis identified significant associations in BRAF,
ERBB2 and NMI. The association between the NMI haplotype and
risk of OC is explained by the single SNP rs11683487. The global
test of haplotype effect was statistically significant for BRAF and
ERBB2. Interestingly, the two haplotypes in ERBB2, which are
significantly associated with increased risk of OC, contain the
opposite allele at each SNP loci. Using HapMap data we evaluated
whether these two putative risk haplotypes in ERBB2 shared an
untagged common variant, but this was not the case. It is possible
that there is an as-yet-unidentified variant that tags both
haplotypes. There may be an allele that is found only in the
protective haplotype of BRAF, which was not captured with our
genotyping.
This study is one of the several in the published literature to use
the multi-centre OCAC to follow-up on putative susceptibility
alleles for OC (e.g., Gayther et al, 2007; Pearce et al, 2008; Ramus
et al, 2008). These studies highlight the importance of consortia for
validating suggested genetic associations from case–control
studies and for identifying novel susceptibility loci for the disease.
In addition to dramatically increasing the power of association
studies, another role of consortia like the OCAC, has been to
implement stringent data quality and genotyping guidelines, which
are likely to minimise reports of false-positive associations.
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Figure 1 Forest plots of tSNP rs11683487 in the NMI gene in ovarian
cancer case–control populations. SEA – SEARCH, UK; MAL – MALOVA,
Denmark; GEO – GEOCS, USA; USC – University of Southern California,
USA; DOV – DOVE, USA; HOP – HOPE, USA; UKO – UKOPS, UK. (A)
Heterozygous and (B) homozygous odds ratios for all invasive ovarian
cancer cases. All cases combined: nominal model – HetOR¼ 0.89 (95% CI
0.79–0.99), HomOR 0.9 (0.78–1.03), Ptrend: 0.0831; dominant model –
OR¼ 0.87 (0.8–0.99), Pdominant: 0.0317.
Table 4 Genetic associations identified in the BRAF, KRAS, ERBB2, NM1 and PIK3CA after histological subtype stratification
Gene SNP Controls Cases HetOR HomOR Ptrend
Endometrioid subtype
ERBB2 rs1801200 2916 263 1.16 (0.88–1.52) 1.71 (1.05–2.76) 0.0389
PIK3CA rs2865084 2039 183 1.60 (1.03–2.50) 0.30 (0.22–0.42) 0.0344
Mucinous subtype
BRAF rs10487888 2694 180 1.32 (0.86–2.03) 1.61 (1.03–2.53) 0.0357
rs1267622 2880 187 0.67 (0.48–0.94) 0.71 (0.35–1.43) 0.0278
rs17695623 2901 186 0.47 (0.26–0.86) 0.79 (0.10–6.08) 0.0191
KRAS rs12822857 2901 187 0.74 (0.53–1.04) 0.63 (0.41–0.96) 0.0232
rs6487464 2895 192 0.61 (0.44–0.85) 0.76 (0.50–1.18) 0.0379
rs10842514 2885 188 1.13 (0.78–1.64) 2.02 (1.35–3.01) 0.0006
NMI rs11683487 2565 154 0.67 (0.47–0.96) 0.62 (0.39–0.99) 0.0269
SNP¼ single-nucleotide polymorphism.
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In conclusion, we genotyped 34 tSNPs that tag the common
variants in BRAF, ERBB2, KRAS, NMI and PIK3CA in OC cases and
controls. We found borderline evidence of a statistically significant
association with invasive OC, for a SNP in NMI and haplotypes in
BRAF and ERBB2. Further studies will be needed to confirm if this
genetic risk association is real or not.
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